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Abstract: Human TP53 gene is characterised by a polymorphism at codon 72 leading to an Arginine‐to‐Proline (R/P)
substitution. The two resulting p53 isoforms have a different subcellular localisation after stress (more nuclear or more
mitochondrial for the P or R isoform, respectively). p53P72 variant is more efficient than p53R72 in inducing the expression
of genes involved in nuclear DNA repair. Since p53 is involved also in mitochondrial DNA (mtDNA) maintenance, we
wondered whether these p53 isoforms are associated with different accumulation of mtDNA damage. We observed that
cells bearing p53R72 accumulate lower amount of mtDNA damage upon rotenone stress with respect to cells bearing
p53P72, and that p53R72 co‐localises with polymerase gamma more than p53P72. We also analysed the in vivo
accumulation of heteroplasmy in a 300 bp fragment of mtDNA D‐loop of 425 aged subjects. We observed that subjects with
heteroplasmy higher than 5% are significantly less than expected in the p53R72/R72 group. On the whole, these data
suggest that the polymorphism of TP53 at codon 72 affects the accumulation of mtDNA mutations, likely through the
different ability of the two p53 isoforms to bind to polymerase gamma, and may contribute to in vivo accumulation of
mtDNA mutations.

INTRODUCTION

plete oxygen reduction due to electron leakage from the
transport chain and therefore are very susceptible to
oxidative damage as well as to other mutagenic lesions,
also because of a limited capability of their repair
systems [2].

Mitochondrial DNA (mtDNA) is a small, doublestranded circular molecule of 16,569 bp that is
contained in many copies inside mitochondria,
packaged into multimeric complexes called nucleoids
made up of proteins and nucleic acids [1]. MtDNA
molecules are particularly exposed to the reactive
oxygen species (ROS) that are formed by the income-
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A key molecule for mtDNA stability is polymerase
gamma (polg), which is the sole mitochondrial
polymerase and plays an essential role in both
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replication and repair of the mtDNA [3,4]. Human polg
is a heterotrimer that contains a 140 kDa catalytic
subunit and a homodimer of accessory subunits. A polg
defective in proofreading activity has been associated to
a phenotype of accelerated aging in a murine model
[5,6]. Alterations in the polymerase and exonuclease
activity of polg induce an increase in the frequency of
mtDNA mutations [3,7] and mutations of POLG1 gene
are associated with a number of diseases [8-10]. Data
also suggest that polg is likely involved in the aging
process [11] and in the pathogenesis of a series of
diseases in which mtDNA instability plays a pathogenic
role, such as age-associated sarcopenia and Parkinson’s
Disease [12,13]. Nevertheless, the molecular details by
which polg ensures mtDNA integrity are still to be
elucidated.

centenarians [20,28]. The in vivo functional importance
of such a polymorphism is demonstrated by the fact that
p53R72 homozygotes and p53P72 carrier subjects have a
different survival after age 85 (greater for p53P72
carriers) as well as a different cancer incidence and
survival after cancer diagnosis [29-31].
It has been reported that p53P72 is more able than
p53R72 in promoting nuclear DNA repair [32]. Since as
summarised above the two p53 isoforms have a
different tendency to localise at mitochondria, we then
wondered whether they can differ also in capability to
maintain mtDNA stability, and whether this may occur
through a differential binding to mtDNA replisome
components such as polg. To check this hypothesis we
performed in vitro as well as in vivo studies whose
results suggest that this is the case.

It has been reported that p53 plays a role in the
maintenance of mtDNA integrity [14-17]. TP53 gene
has a well-known crucial role in the response to DNA
damage, in cell cycle regulation, apoptosis and cell
senescence. Recent studies from our and other
laboratories demonstrated that p53 protein, the product
of TP53 gene, in response to an oxidative stress not
only behaves as a transcription factor at nuclear level,
but can also translocate at mitochondrial level [18-20].
In the mitochondria, p53 could bind to Bcl-xL and to
other proteins to induce mitochondrial-mediated
apoptosis independently from transcriptional activity
[18-21]. Moreover, it has been observed that a fraction
of p53 is present in mitochondria of non-stressed cells
[21]. It has been reported that within mitochondria p53
can bind to polg and modulate its activity [14,15].
Indeed, it has been observed that in TP53 knock out
animals the base excision repair activity is less efficient,
and that p53 can bind to polg in in vitro cellular models,
increasing polg-mediated mtDNA replication and
suppressing the mutagenic effect of ROS and ethidium
bromide [14,15,22]. It is also reported that in mtDNA at
least one consensus sequence for p53 binding does exist
[23].

RESULTS
p53R72 localises with extranuclear 8-oxo-dG more
than p53P72 and protects mitochondrial function
We could confirm that, as previously reported for ex
vivo cells [20], also ectopically expressed p53 tends to
localise differently according to the polymorphism at
codon 72. Figure 1 shows the confocal analysis of p53
null HCT116 cells transfected with pCMS-EGFP
plasmid, either empty or expressing the arginine or
proline TP53 allele. Three representative cells are
presented. It can be appreciated that upon treatment
with 100 nM rotenone (an inhibitor of mitochondrial
respiration complex I) for 24 hours, while cells
transfected with the empty vector resulted to have a
widespread EGFP fluorescence not clearly associated
with any subcellular structure (upper panels), cells
transfected with p53R72-expressing plasmid showed a
dotted EGFP fluorescence largely overlapping with
MitoTracker Red CMX-Ros (MTR) fluorescence
specific for mitochondria (central panels), a
phenomenon which is much less evident when p53P72expressing plasmid is used (lower panels).

TP53 gene has a number of natural allelic variants,
among which those due to the polymorphism at codon
72 (in the exon 4) are of particular interest. This
common polymorphism causes a C-to-G transversion
that in turn leads to a Proline-to-Arginine substitution in
the p53 protein. The two resulting variants (p53P72 and
p53R72) are different as far as the capability to modulate
apoptosis, to translocate to mitochondria, to be
degraded by proteasome and to bind to MDM2 [24-27].
It has been observed that these differences become
significant in ex vivo models as the age of the donor
increases, being negligible in cells from young donors,
and statistically significant in cells from old people and
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Upon treatment with rotenone, we observed by confocal
microscopy and flow cytometry (Figure 2A and 2B) a
consistent accumulation of 8-oxo-dG fluorescence,
which appears to be localised outside the nucleus of
cells (Figure 2A). When comparing cells transfected
with either EGFP-p53R72 or EGFP-p53P72 expressing
plasmids, we observed that upon rotenone treatment
p53R72 tends to co-localise with 8-oxo-dG extranuclear
fluorescence more than p53P72 (Figure 2C, arrows). On
the other side, p53P72 has a preferential nuclear
localisation, as showed by the perfect overlap with
Hoechst staining. This indicates that rotenone treatment
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organelle bearing extranuclear DNA, and that p53R72
isoform tends to co-localise with these adducts.

induces formation of 8-oxo-dG adducts in
mitochondria, the target of rotenone and the sole

Figure 1. Different localisation of p53 isoforms after

rotenone treatment. p53‐/‐ HCT116 cells transfected
with empty EGFP pCMS plasmid (upper panels), EGFP‐
72
72
p53R pCMS plasmid (central panels), or EGFP‐p53P
pCMS plasmid (lower panels) and counterstained with
MitoTracker Red (MTR). Cells transfected with the
empty vector show a diffused EGFP fluorescence, not
associated with any cell structure; in cells transfected
with the plasmids expressing the p53 isoforms, a
different subcellular localisation is noticed, as assessed
by counter‐staining with the mitochondrial‐specific
72
probe MTR. In particular, when EGFP‐p53R pCMS
plasmid is used, EGFP fluorescence, associated to p53
protein, appears to be not nuclear but rather co‐
localised with MTR fluorescence, indicating that p53
has a mitochondrial localisation (white dots indicate
points of overlapping of the two fluorescences).

Figure 2. Co‐localisation of p53 isoforms with

damaged mtDNA. (A) p53‐/‐ HCT116 cells treated with
100 nM rotenone for 24 hours and stained for 8‐oxo‐dG
and revealed with RPE‐conjugated secondary moAb
(red fluorescence). Nuclei are counterstained with
Hoechst 33258. Punctuated, cytoplasmic red
fluorescence indicates that 8‐oxo‐dG accumulates in
mitochondria but not nuclei upon rotenone treatment.
(B) flow cytometric detection of 8‐oxo‐dG after
‐/‐
rotenone treatment. C: p53 HCT116 cells transfected
72
with either EGFP‐p53R or EGFP‐p53P72 pCMS plasmid
and treated as in A. Arrows indicate the points in which
8‐oxo‐dG (red fluorescence) and p53 (green
fluorescence) co‐localise (yellow dots in the merged
picture). Note that in the case of p53R72 the green
fluorescence is diffused in the cytoplasm and tends to
72
accumulate in mitochondria, while in the case of p53P
the green fluorescence is mainly localised to the
nucleus.
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Figure 3. Flow cytometry analysis of p53‐/‐ HCT116 cells

72
72
transfected with either EGFP‐p53R or EGFP‐p53P pCMS
plasmid. After 24 hours from transfection, cells were treated
with 100 nM rotenone and incubated for additional 24 hours,
then stained for 8‐oxo‐dG or TMRM (see materials and
methods). (A) transfection efficiency. Cells contained in R1 are
considered EGFP‐positive. Ctr: non‐transfected cells. (B) 8‐oxo‐
dG detection. The cells in (R1) and (not R1) are evaluated for
8‐oxo‐dG fluorescence (RPE). Numbers represent the
percentage of cells with high 8‐oxo‐dG fluorescence and are
expressed as mean ± st. dev. of three independent
experiments. As showed EGFP‐negative cells (not R1, not
expressing p53) are almost all positive for 8‐oxo‐dG
fluorescence (more than 90%), while when considering EGFP‐
positive cells (R1, expressing p53), the cells that were
72
transfected with p53R which resulted positive for 8‐oxo‐dG
decreased to 69%, with respect to 92% of those that were
transfected with p53P72. See text for comment. (C)
Mitochondrial membrane potential (MMP) analysis. The cells
in (R1) were evaluated for MMP by using the potentiometric
dye TMRM. Black line: control cells; red line: rotenone
treatment. Decrease in MMP was expressed as the difference
(Δ) of TMRM fluorescence intensity between rotenone‐treated
and control cells. Cells positive for EGFP‐p53R72 (left panel)
display a lower decrease in MMP with respect to those
positive for EGFP‐p53P72 (right panel). The graphic shows data
related to 3 independent experiments (mean ± st. dev.) *
Student’ t test p= 0.022. NT, not transfected.

In order to have a semi-quantitative evaluation of the
accumulation of 8-oxo-dG in cells transfected with
either EGFP-p53R72 or EGFP-p53P72 we set up a flow
cytometric test in which transfected HCT116 cells were
treated with rotenone 100nM for 24 hours and then
immunostained with anti-8-oxo-dG moAb. Cells
positive for EGFP (expressing p53) were electronically
gated and compared for 8-oxo-dG specific fluorescence
(RPE fluorochrome) with EGFP-negative cells (not
expressing p53). Results are reported in Figure 3, where
a representative experiment is reported together with
mean ± st.dev. of three separate experiments. Figure 3A
shows the transfection efficiency, which is about 16%
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for both plasmids. Cells considered EGFP-positive are
gated in Region 1 (R1) and represented in red dots.
Figure 3B shows the 8-oxo-dG fluorescence of cells not
gated in R1 (upper panels) and gated within R1 (lower
panels). As shown, EGFP-p53-negative cells (not R1)
are almost all positive for 8-oxo-dG fluorescence (more
than 90%), no matter of the plasmid used for the
transfection procedure (EGFP-p53R72 pCMS vs EGFPp53P72 pCMS, p=0.34, two-tailed Student’ t test). On
the contrary, when considering EGFP-p53-positive cells
(R1), the percentage of cells positive for 8-oxo-dG is
quite different depending on the p53 isoform the cells
are transfected with. Indeed, this percentage is
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consistently lower for cells expressing the p53R72
isoform with respect to those expressing the p53P72 one
(69.6 ± 1.6 vs 92.1 ± 4.5, p=0.003). An analysis of
Mitochondrial Membrane Potential (MMP) made with
the potentiometric dye TMRM also indicated that
EGFP-p53R72-positive cells are less susceptible to
undergo MMP decrease with respect to those positive
for EGFP-p53P72, suggesting that these cells have a
better preserved mitochondrial function (Figure 3C).
p53R72 binds to polg more than p53P72 and
protects mtDNA integrity
A possible mechanism to explain this difference could
be the reported different capability of the two p53
isoforms to induce apoptosis, so that heavily damaged
cells transfected with p53R72 isoform would be more
prone to apoptosis than those transfected with p53P72,
but this seems not to be the case. Indeed, transfection
appears to induce massive apoptosis, but with no
difference between the two plasmids (data not shown).
Another possible mechanism is the different capability
of the two isoforms to localise at mitochondrial level.
This may favour the binding and activation of polg, the
polymerase involved in mtDNA repair. We then
checked the co-localisation of p53 isoforms with polg.
After checking for anti-polg antibody specificity
(Figure 4A), we found that EGFP-p53R72 co-localises
with polg more than EGFP-p53P72 (Figure 4B, arrows).
To further strengthen these data, we generated stably
transfected PC3 cells expressing either p53R72 or
p53P72, conjugated with HA epitope tag, and performed
co-immunoprecipitation assay (Figure 4C). To this
purpose, cells were exposed to10 nM rotenone, for 72
hours then protein were precipitated for polg and
assayed with anti-HA antibody. These experiments
confirmed that p53R72 is more bound to polg than
p53P72. The experiment was repeated with different
exposure times. Other than 72 hours exposure, cells
were treated for 6 or for 6 hours then recovery until 72
hours (6h+r). Also in this case p53R72 resulted to be
more bound to polg than p53P72 except that at point
6h+r (Figure 4D).

Figure 4. Co‐localisation of p53 and polg. (A) Confocal analysis
of p53‐/‐ HCT116 non‐transfected cells stained with anti‐polg
antibody alone or with the TRITC‐conjugated secondary
antibody; Western Blot analysis of specificity of the anti‐polg
antibody on cytoplasmic and nuclear fractions obtained from HL‐
60 cells and human hepatocytes. As shown, the band
corresponding to the molecular weight of polg is present only in
the cytoplasmic fractions. (B) Confocal analysis of p53‐/‐ HCT116
72
cells transfected with EGFP‐p53R (upper panels) or EGFP‐
72
p53P (lower panels) pCMS plasmids and treated with 100 nM
rotenone for 24h. It is possible to observe that only in the case
of p53R72 many points of co‐localisation are visible (arrows). (C,
D) Co‐Immunoprecipitation assay on stably transfected PC3
cells. In C cells were treated for 72h with 10 nM rotenone. R=
72
72
p53R ; P= p53P . The lanes indicated as supernatant show the
amount of p53 expressed by the cells. In D cells were exposed to
10 nM rotenone for 6h, 72h, 6h and recovery until 72h (6h+r).

It is reported that mutator mice with a polg deficient in
proofreading activity accumulate both mtDNA point
mutations and deletions [33]. We then checked whether
exposure to rotenone in cells expressing either one or
the other p53 isoform could induce an accumulation of
mtDNA damage such as large deletions (e.g. the 4,977
bp), assessed by nested PCR and Long PCR. Also, since
this deletion leads to an increase in mtDNA copy
number [34], we also checked whether mtDNA copy
number, assessed by Real-time PCR, is affected in

stably transfected cells. These tests were performed on
total DNA extracted from stably transfected PC3 cells
before and after treatment with 10 nM rotenone. No
difference in terms of mtDNA copy number was
observed (Figure 5A), even if a trend of higher copy
number is present for p53P72 expressing cells.
Nevertheless, both Nested PCR and Long PCR
indicated that these cells accumulate higher levels of
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deletions in the mtDNA as compared to those
expressing p53R72 (Figure 5B,C).

As a whole, these data suggest that TP53 codon 72
polymorphism affects accumulation of damage in
mtDNA likely by modulating the efficiency of mtDNA
repair. Data presented in this paper suggest that this
modulation occurs through the binding of p53 to polg,
even if other possible mechanisms can not be excluded.
TP53 codon 72 polymorphism is associated with
mtDNA heteroplasmy in vivo
In order to investigate whether TP53 codon 72
polymorphism has an impact on mtDNA stability in
vivo, thus reflecting the differences we observed for the
two isoforms in vitro, we analysed the correlation
between mtDNA heteroplasmy and TP53 codon 72
genotype in white blood cells (WBC) from 425
volunteers of old age (from 60 to 108 years of age),
where accumulation of somatic mtDNA mutations are
more likely to occur. Heteroplasmy was assessed by
DHPLC in a segment of the mtDNA D-loop from nt
16531 to nt 261, spanning between hypervariable region
(HVR) 1 and 2. Table 1 shows the distribution of
mtDNA heteroplasmy in subjects with different
genotypes at TP53 codon 72. We found that subjects
with different level of heteroplasmy are not randomly
distributed across the three genotypes (p=0.0147). In
particular, considering a heteroplasmy threshold of 5%,
we observed that homozygous TP53R72/R72 subjects
with a heteroplasmy over 5% are less frequent than
expected, while heterozygous subjects with a
heteroplasmy over 5% are more frequent than expected.
A univariate logistic analysis, where the genotype at
TP53 codon 72 was the independent variable and the
presence/absence of high level of heteroplasmy was the
dependent variable, showed that p53R72 acts as a
recessive allele on the trait presence/absence of high
level of heteroplasmy. On the whole these data suggest
that homozygous TP53R72/R72 genotype is associated
with lower accumulation of heteroplasmy in the
considered mtDNA region.

Figure 5. Measurements on mtDNA of stably transfected PC3
cells. Cells were exposed to 10 nM rotenone for 6h, 72h, and 6g
and recovery until 72h (6h+r). (A) copy number assessed by
Real‐time PCR. Data are expressed as ratio between the levels of
ND1 and actin genes, and are the average value of three
72
separate measurements ± st. dev. White columns: p53R
72
expressing cells; black columns: p53P expressing cells. (B)
Nested PCR specific for the 4,977 bp deletion. A representative
experiment out of three is showed. 1,5: control; 2,6: 6h; 3,7:
6h+r; 4,8: 72h; Δ4,977: DNA from a subject carrying the 4,977 bp
deletion. C: Long PCR for multiple mtDNA deletions. Numbers
legend as in B; M: marker 1 Kb; C: non‐transfected PC3 cells; N:
DNA from PBMC of a young subject.

Table 1. Distribution of TP53 codon 72 genotypes across the two groups of subjects defined on the basis of the in vivo mtDNA
heteroplasmy levels. Obs: observed; Exp: expected under random combination between heteroplasmy and TP53 genotypes (p‐value=
p=0.0147).
Levels of
heteroplasmy

Genotype
RR

Total

RP

PP

Obs (%)

Exp

Obs (%)

Exp

Obs (%)

Exp

≤ 5%

127 (57.2)

116

75 (33.8)

87.2

20 (9.0)

18.8

222

> 5%

95 (46.8)

106

92 (45.3)

79.8

16 (7.9)

17.2

203

Total

222
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Thus, it seems that the capability to localise at
mitochondria can affect not only the activity of p53 as
an inducer of transcription-independent apoptosis, but
also as a cofactor of mtDNA repair, therefore
influencing
mtDNA
stability and
eventually
mitochondrial efficiency.

DISCUSSION
mtDNA integrity tends to decrease with age, as
demonstrated by the accumulation of point mutations
and deletions in a variety of tissues during aging in
humans, monkeys, and rodents [35,36]. The
accumulation of somatic mtDNA mutations has likely a
causative role in the aging of the organisms, as
suggested by animal models such as the mutator mice
lacking the proofreading activity of polymerase gamma
(polg) [5,6,37]. Therefore, it is reasonable to
hypothesise that factors impinging upon the stability of
mtDNA can affect the rate of aging in animals and
humans.

To test whether these in vitro findings have an in vivo
counterpart, we analysed the levels of mtDNA
heteroplasmy in WBC from subjects with different
genotype at TP53 codon 72. Indeed we found that
subjects with p53R72/R72 genotype have a lower chance
to accumulate heteroplasmy in the mtDNA control
region (CR), suggesting that also in vivo this
polymorphism has an effect on mtDNA stability.
Previous studies had shown that the accumulation of
somatic mutations in the mtDNA CR is genetically
influenced by nuclear genome variability [43,44]. The
variability of TP53 codon 72 may then be part of the
genetic “machinery” affecting the accumulation of
mtDNA somatic mutations.

p53 has a well-known role in inducing DNA repair,
apoptosis, block of cell cycle and induction of cell
senescence. More recently, other roles have been
discovered for p53, regarding autophagy, glucose
metabolism and miRNA maturation [37-40]. Among
these new functions, a role in controlling mtDNA
replication and repair has been proposed for p53
through the binding of polg [15] and TFAM [41]. As
summarised above, it is known that human TP53 is
characterised by a polymorphism at codon 72 that yields
two isoforms of the p53 protein differing by one
aminoacid at the level of the N-terminus Proline Rich
Region, and that these two isoforms differ in the
capability to localise within the cell. Since one of these
two isoforms (p53R72) can efficiently localise at
mitochondrial level, we wondered whether in cells
bearing this isoform, the accumulation of alterations at
the level of mtDNA was lower than in cells bearing the
other isoform (p53P72), and whether this could have an
in vivo consequence on the accumulation of mtDNA
mutations. As a whole, our data suggest that this is the
case. The mechanism by which this occurs seems to be
an interaction of p53 with polg. We can not exclude,
however, that other possible mechanisms take place
simultaneously. For instance, it is reported that p53
binds also to HmtSSB and that this binding slightly
increases the exonuclease activity of p53 capable to
eliminate 3’- 8-oxo-dG nucleotides [42]. Also the
binding to TFAM likely renders mtDNA more
accessible to repair enzymes [17].

It is to note that in previous reports, high levels of
heteroplasmy in the mtDNA CR seem to be a genetic
characteristic of human longevity, being present in
centenarians and their offspring [43,44] as well as in
90+ sibpairs [45]. This may suggest that mtDNA
heteroplasmy should not to be considered detrimental in
all cases, being possible that certain types of
heteroplasmy can provide the cell with some (still
unknown) type of survival signalling. As an example,
the substitution at position 150 of mtDNA CR found in
centenarians seems to favour mtDNA replication [43].
If this is true, one may expect that TP53 codon 72
polymorphism can affect the survival at old age through
the capability to control, at least in part, the level of
heteroplasmy of the mtDNA CR. Previous studies from
our group indicate that TP53 codon 72 polymorphism
does not affect the human lifespan, when large cohorts
of subjects from young people to centenarians are
analysed [46]. However, when a more restricted age
range is considered, it appears that 85+ subjects
carrying the TP53P72/P72 genotype have a survival
advantage over those carrying the TP53R72/R72
genotype [30]. We surmise that the effect of the TP53
codon 72 polymorphism on the level of mtDNA CR
heteroplasmy might contribute to this survival
advantage. Further investigations are needed to test
whether this hypothesis is correct.

As a whole, the data reported in this paper and other
present in the literature suggest that the two isoforms
p53P72 and p53R72 are more prone to ensure the repair
of the nuclear or the mitochondrial genome,
respectively. Indeed, it has already been reported that
cells that express in vitro the p53P72 isoform have a
greater capability to repair damages of nuclear DNA
and display a reduced production of micronuclei with
respect to cells that express the p53R72 isoform [32].
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MATERIALS AND METHODS
Cells culture and treatment. p53 null HCT116 cells
were a kind gift of Bert Vogelstein (Sidney Kimmel
Comprehensive Cancer Center, Johns Hopkins
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University, Baltimore, MD, USA). They were cultured
in McCoy’s medium, pH 6.9, supplemented with 10%
FCS and penicillin (100 units/mL)/streptomycin (100
mg/mL) in 5% CO2 humidified atmosphere at 37°C.
They were collected at log phase of growth, counted
and seeded in 6-wells plates at the concentration of
50,000/ml (total volume 2 ml). After 48 hours of
culture, medium was changed and the cells were
transiently transfected with 3 ng of pCMS-EGFP
plasmid, either empty or expressing the EGFP-p53R72
or EGFP-p53P72 allele, using JetPEI transfection
reagent (Polyplus transfection) according to the
manufacturer instructions for additional 24 hours, after
which 100 nM rotenone was added and left to stay for
24 hours unless otherwise indicated. After this time
cells were collected and analysed by either confocal
microscopy or flow cytometry. In set-up experiments
cells were analysed for the level of apoptosis by
staining with Propidium Iodide (PI) in hypotonic
solution as previously described [28]. Analysis was
performed in linear scale in order to detect also possible
accumulation in G2 phase. No difference in terms of
percentage of apoptotic cells was found between cells
transfected with either EGFP-p53R72 or EGFP-p53P72
expressing plasmids; accumulation in G2 was also not
observed under rotenone treatment (data not shown).

with blue COH diode (405nm/25mW), Ar
(458nm/5mW)
(476nm/5mW)
(488nm/20mW)
(496nm/5mW)
(514nm/20mW),
HeNe
(543nm/1.2mW), HeNe (594nm) (Orange) and HeNe
(633nm/102mW) lasers. The microscope and the AOBS
system were controlled by the LCS software (Leica).
The slides were observed under a HCX PL APO
40x/1.25 – Oil- objective. In order to avoid overlaps
between fluorochrome excitations/emissions during
scanning procedures, images where acquired in separate
channels for each fluorochrome. Merged figures derived
from the software-assisted integration of horizontal
xyλ-sections (line average= 2; number of scansions per
line= 3). Colocalisation of different fluorochromes was
ascertained using the measuring and analysis functions
of LCS software Version 2.0, 2001 (Leica, Germany).
Flow cytometry. Cytofluorimetric analyses were
performed using a FACScalibur cytometer (BD),
equipped with an argon laser on a minimum of 10,000
cells per sample, acquired in list mode. Briefly, cells
were detached from substrate with 1% trypsin in PBS
for 2 minutes and treated as described for 8-oxo-dG
detection. Analysis of 8-oxo-dG specific fluorescence
was performed on cells electronically gated for being
positive for EGFP fluorescence (meaning that they are
expressing p53) and compared to those negative for
EGFP (meaning that they are not expressing p53) in the
same sample, thus avoiding experimental variability.
The experiments were repeated three times.
Mitochondrial Membrane Potential (MMP) was
assessed by using the potentiometric dye Tetramethylrhodamine methyl esther, perchlorate (TMRM,
Molecular Probes). Staining with 150 nM TMRM for
15 min at room temperature was followed by washing
in PBS and analysis. Multiparametric analysis allowed
for the simultaneous detection of TMRM (red) and
EGFP (green) fluorescences.

Confocal microscopy. After treatment, cells were
collected and stained by immunocytochemistry for polg
or 8-hydroxy-2’-deoxyguanosine (8-oxo-dG). Briefly,
cells were seeded into wells containing a sterile glass
coverslip for confocal microscopy. After the treatments
(see above), cells were washed with PBS+1% BSA,
fixed in formaldehyde 2% in PBS for 10 minutes at RT
and permeabilised with saponin 0.2% in PBS for further
10 minutes at RT. For polg detection, cells were
incubated with anti-polg rabbit polyclonal antibodies
(Pierce) (dilution 1:200) for 1 hour at 4°C and goat-antirabbit
TRITC-conjugated
IgG(H+L)
(BioFX
Laboratories) (dilution 1:400) for 1 hour at 4°C.
Coverslips were then mounted onto a glass slide with
mowiol, sealed and kept at 4°C in the dark until
confocal analysis. For 8-oxo-dG detection, after fixation
and permeabilisation, the cells were treated with 2N
HCl for 30 minutes at RT, followed by pH reequilibration with Borax solution 0.1M. Slides were
then washed with PBS+1% BSA and incubated with
anti-8-oxo-dG mouse monoclonal antibodies (Trevigen)
(dilution 1:1000) for 4 hours at 4°C and goat-antimouse RPE-conjugated monoclonal antibody (Dako)
(dilution 1:250) for 1 hour at 4°C. In some experiments,
bis-benzimide (Hoechst 33258) 250ng/ml was added to
counterstain nuclei. Slides were analysed with a “Leica
DMIRE2” inverted research microscope connected with
a TCS SP2-AOBS system (Leica, Germany) equipped
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Generation of stable transfectant. In order to obtain a
higher percentage of transfected cells, we generated
stably transfected cell lines expressing the two p53
isoforms using PC3 p53 null cells. An HA-epitope tag
was added to the N-terminal position of p53 cDNA
sequence of both codon 72 Arginine and Proline
isoforms using PCR with the following primers:
Forward, p53 NotI HA tag 5'- GCG GCC GCG GCG
CGC CCG GGA TCC TGA TCA GCA GGC GCC
ATG TAC CCA TAT GAT GTT CCA GAT TAC GCT
GAG GAG CCG CAG TCA GAT CCT -3'; Reverse,
p53 BglII site 5'- GCA GAT CTA TTT AAT TCA GTC
TGA GTC AGG CCC TTC T -3'. The restriction sites
NotI and BglII were used to ligate the PCR product into
the retrovector LNXCO3 that supports IPTG inducible
expression.
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measurement of nuclear DNA encoded β actin gene.
The primers sequences are as follow: ND1: L3485ND1_Forward: CCC TAA AAC CCG CCA CAT CT;
H3532-ND1_Reverse: GAG CGA TGG TGA GAG
CTA AGG T. β Actin: Forward: ACC CAC ACT GTG
CCC ATC TAC; Reverse: TCG GTG AGG ATC TTC
ATG AGG TA. The quantitative PCR was conducted
on a Rotor gene Q 6000 system (Qiagen) in a 10 μl
reaction in different tubes containing 0.3μM each of the
forward and reverse primer (ND1 and β actin genes), 15
ng of DNA sample and 1X Mesagreen reaction mix
(Eurogentec). The PCR condition was set as follow:
95°C for 5 min, 40 cycles at 95°C 15 s and 60 °C 1 min.
The Ct Values for both the genes were determined.
Each measurement was carried out in duplicate and
repeated three times, the same calibrator sample was
used in each run. The analysis was performed
normalising against the calibrator and the result was the
average of the three repeated experiments.

PC3 subline 3'SS6 was derived after transfection with
the murine ecotropic retrovirus receptor and LacI
repressor genes as previously described [47]. The
LNp53CO3 vector for both isoforms was constructed by
cloning the entire coding sequence of the human p53
cDNA in the NotI and BglII sites of IPTG-inducible
retroviral vector LNXCO3 [47]. Insert-free vector
LNXCO3 was used for control infections. Both
isoforms of LNp53CO3 and LNXCO3-transduced cell
populations were selected with 600ug/ml G418. Cell
lines were cloned by plating 500-2000 cells per 150 mm
tissue culture plate and individual colonies collected.
Expression in PC3 cells was induced with 100 μM
IPTG for two weeks and clones were selected for 100%
expression, evaluated by flow cytometry (Cytomics ™
FC 500, Beckman Coulter Inc. Brea, Ca) using an
antibody to the HA-epitope (Covance Inc., Emeryville,
Ca). For flow cytometry, PC3 cell lines expressing both
isoforms of p53 were fixed with 70% ethanol and
permeabilised with PBS containing 0.2% Triton X-100.
Staining was performed using 1:1000 HA-epitope
antibody and a fluorescent secondary antibody.

Nested PCR. A nested PCR analysis was performed to
screen for low levels of the 4,977 bp deletion in
mtDNA. Primers and PCR conditions are previously
reported [34], briefly the PCR condition was: predenaturation at 94°C for 5 min, then 30 cycles at 94°C
for 10s, 58°C for 45 s and 72°C for 50 s; and a final
extension at 72°C for 10 min. PCR products were
visualised in a 2% agarose gel. The presence of the
4977-bp deletion was indicated by the appearance of a
358 bp band, which was verified by the presence of a
positive control sample harbouring the 4,977 bp
deletion.

To confirm that the cells retained the correct isoform of
p53, they were analysed by retrotranscription and
amplification of the gene introduced with the viral
vector, and digestion with BstUI restriction enzyme.
PCR yielded a product of about 1,252 bp, as expected,
and digestion with BstUI produced three fragments
(722, 284 and 252 bp) from cells transfected with the R
isoform, and two fragments (722 and 536 bp) from
those transfected with the P isoform (data not shown),
confirming the attribution of the isoform expressed by
the cells.

Long PCR. The 11.3 kb long-PCR to amplify almost
full-length of mtDNA was carried out to detect mtDNA
multiple deletions using forward primer corresponding
to L-strand nt-3485 to 3519, backward primer H-strand
nt-14820 to 14786 and Takara LA Taq DNA
polymerase (Takara Shuzo Corp., Japan) as previously
reported [48]. Briefly the PCR condition was: predenaturation at 94°C for 3 min, then 30 cycles at 98°C
for 10s and 68°C for 15 min followed by a final
extension at 72°C for 12 min. PCR products were
visualized in a 1% agarose gel. The 11.3-Kb band
represents the wild type mtDNA, all the other bands
indicate the deletions.

Immunoprecipitation and immunoblotting. p53
expression in PC3 cells was induced with 100 μM
IPTG. Subconfluent cells were treated with 10 nM
rotenone (Sigma-Aldrich, Inc. St. Louis, MO) for 72 h.
Rotenone treated and untreated cells were extracted
with Lysis Buffer II (Pepscan Presto, Lelystad,The
Netherlands), sonicated and centrifuged at 4000 x g
before immunoprecipitation. To immunoprecipitate
DNA polymerase gamma, 1000 μg of cell extract was
incubated with 1.6 μg of a rabbit polyclonal antibody
(Pierce PA121791, Pierce Rockford, IL, USA) for 5
hours at 4o C. The immune complexes were captured
with protein A/G sepharose. The immunoprecipitates
were analysed by western blot using an antibody to the
HA-epitope tag on both p53 isoforms.

In vivo correlation between mtDNA heteroplasmy
and TP53 codon 72 genotype
Sample. A total of 425 unrelated subjects (191 men and
234 women, age range 60-108 years; median ages 83.09
(±15.04) and 86.06 (±13.29) years, respectively) were
recruited to participate in this study. All the subjects
were born in Calabria (Southern Italy) and their
ancestry in the region has been ascertained up to the

mtDNA integrity assessment
mtDNA copy number. The mtDNA content was
measured by real-time PCR on a mtDNA encoded gene
rarely deleted (ND1) normalised by simultaneous
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grandparents’ generation. The sample has been
collected in the frame of several recruitment campaigns
carried out for monitoring the quality of aging in
Calabria from 2002. Younger subjects were contacted
through general physicians. Subjects older than 90 years
were identified through the population registers and
then contacted by specialised personnel and invited to
join the study. Each subject was submitted to a homebased interview by a trained operator, with the
administration of a structured questionnaire, validated at
European level. The questionnaire was aimed to the
collection of socio-demographic information, evaluation
of physical, cognitive, depressive status, sensory
deficits, medications, and self-reported health status. In
addition, common clinical haematological tests were
performed. Subjects with dementia and/or neurologic
disorders were not included. All the subjects had given
informed consent for studies on aging carried out by our
research group. White blood cells (WBC) from blood
buffy coats were used as source of DNA.
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